Table 4.

B-cell directed versus complement-directed therapies in CAD.

Therapy	Study (Reference)	Overall efficacy	Time to response	Effect on hemolysis	Effect on circulatory symptoms	Duration of therapy	Response duration	Toxicity	Costs
Rituximab monotherapy	Berentsen et al., 2004 (78); Schöllkopf et all. 2006 (79)	Modest	Sometimes long	Moderate	Moderate	Short	Short; therapy can be repeated	Low	Moderate
Bendamustine plus rituximab	Berentsen et al., 2017 (81); 2020 (61)	High	Sometimes long	High	High	Short	Long. Some patients may be cured.	Moderate	Moderate
Sutimlimab	Röth et al., 2021 (70); 2022 (77)	High	Short	High	None	Indefinite	Long (provided continued treatment)	Low	Very expensive